차전자피 관련 과민성 대장 증후군(IBS)
B 근거 적어도 하나의 무작위 시험이 이를 지지하며, 대체로 일관된 결과를 보입니다.ACG는 IBS에서 불용성 섬유보다 수용성 섬유(차전자피)를 권장합니다. 전반적인 IBS 증상을 개선하며 IBS-C에서 특히 유익합니다. 전반적 증상 개선의 치료필요수는 7입니다.
<\/script>\n`;
},
get iframeSnippet() {
const domain = 'gutcited.com';
const params = 'ingredient\u003Dpsyllium\u002Dhusk\u0026condition\u003Dibs';
return ``;
},
get activeSnippet() {
return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet;
},
copySnippet() {
navigator.clipboard.writeText(this.activeSnippet).then(() => {
this.copied = true;
setTimeout(() => { this.copied = false; }, 2000);
});
}
}"
@keydown.escape.window="open = false"
@click.outside="open = false">
B
결론
ACG는 IBS에서 불용성 섬유보다 수용성 섬유(차전자피)를 권장합니다. 전반적인 IBS 증상을 개선하며 IBS-C에서 특히 유익합니다. 전반적 증상 개선의 치료필요수는 7입니다.
Key Study Findings
Observational Study
n=97
Survey of Latin American gastroenterologists, specialists in disorders of gut-brain interaction, on the diagnosis and …
Dose: None
vs: None
Outcome: IBS management heterogeneity in Latin America
효과: None
None
대상 집단: Latin American gastroenterologists (DGBI specialists)
Review
The role of dietary fiber in the gastrointestinal tract: when, how and why?
Dose: None
vs: None
Outcome: None
효과: None
None
대상 집단: Review of dietary fiber role in GI tract
Review
The role and therapeutic effectiveness of Plantago ovata seed husk (psyllium husk) in the prevention …
Dose: None
vs: None
Outcome: Colitis severity
효과: None
None
대상 집단: Ulcerative colitis patients
Randomized Controlled Trial
n=314
Sex-Dependent Efficacy of Dietary Fiber in Pediatric Functional Abdominal Pain.
Dose: Dietary fiber (psyllium)
vs: Low fiber diet
Outcome: Abdominal pain frequency
효과: None
None
대상 집단: Children with functional abdominal pain disorders
Randomized Controlled Trial
3 weeks
Double-blind
Nutraceuticals and Pain Disorders of the Gut-Brain Interaction in Infants and Children: A Narrative Review …
Dose: None
vs: Placebo
Outcome: Pain outcomes
효과: None
None
대상 집단: IBS patients
Systematic Review
[Phytotherapeutic recommendations in medical guidelines for the treatment of gastroenterological diseases - a systematic review].
Dose: Peppermint oil, STW-5, psyllium, others
vs: Standard care or placebo
Outcome: Symptom improvement in GI diseases
효과: None
None
대상 집단: Patients with gastroenterological diseases
Key Statistics
8
연구
900
참여자
↑
Positive
B
등급
Referenced Papers
Best practice & …
2025
1 인용
The Medical letter …
2025
The Medical letter …
2025
Revista de gastroenterologia …
2025
The Medical letter …
2025
Gastroenterology
2024
8 인용
Nutrients
2024
5 인용
Przeglad gastroenterologiczny
2024
4 인용
[Phytotherapeutic recommendations in medical guidelines for the treatment of gastroenterological diseases - a systematic review].
Systematic Review
Zeitschrift fur Gastroenterologie
2024
3 인용
Gastroenterology
2024
3 인용
Dietary Fibers in Healthy Children and in Pediatric Gastrointestinal Disorders: A Practical Guide.
Review
Nutrients
2023
43 인용
The American journal …
2023
39 인용
Nutrients
2023
32 인용
Journal of pediatric …
2023
21 인용
Nutrients
2023
4 인용
Journal of pediatric …
2023
1 인용
In persons with constipation or IBS-C, kiwifruit vs. psyllium increased spontaneous bowel movements.
Other
Annals of internal …
2023
Gut
2022
39 인용
American journal of …
2022
18 인용
Expert review of …
2022
8 인용
The Turkish journal …
2021
14 인용
Current opinion in …
2021
6 인용
The lancet. Gastroenterology …
2020
119 인용
The Medical letter …
2020
Journal of the …
2019
171 인용
World journal of …
2019
14 인용
International journal of …
2017
146 인용
Probiotics, fibre and herbal medicinal products for functional and inflammatory bowel disorders.
Review
British journal of …
2017
145 인용
Clinical gastroenterology and …
2017
93 인용
Journal of gastroenterology …
2017
32 인용
Current opinion in …
2017
24 인용
International journal of …
2016
69 인용
Clinical gastroenterology and …
2016
2 인용
Digestion
2014
61 인용
The American journal …
2013
421 인용
Journal of clinical …
2011
30 인용
Alimentary pharmacology & …
2011
3 인용
Canadian journal of …
2011
Current opinion in …
2010
22 인용
BMJ (Clinical research …
2009
296 인용
Australian family physician
2009
12 인용
Prescrire international
2009
BMJ (Clinical research …
2008
550 인용
International journal of …
2007
375 인용
Digestive diseases and …
2006
70 인용
Current treatment options …
2006
24 인용
Systematic review: the role of different types of fibre in the treatment of irritable bowel syndrome.
Systematic Review
Alimentary pharmacology & …
2004
322 인용
Gut
1987
153 인용
Biomedicine & pharmacotherapy …
1986
4 인용
Annals of internal …
1981
91 인용
Annals of internal …
1981
6 인용
IRRITABLE COLON.
Other
JAMA
1964
Dosage & Usage
mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units
일반적으로 사용되는 용량
- general:
- 5-10 g/day (with adequate water)
- ibssupport:
- 5-10 g/day (start low, titrate up over 1-2 weeks)
- constipation:
- 10-20 g/day in divided doses with at least 240 mL water per dose
상한량: Well-tolerated up to 30 g/day with adequate fluid intake
연구에서 사용된 용량
| 용량 | 기간 | 효과 | N |
|---|---|---|---|
| None | -- | Mixed | 97 |
| None | -- | Mixed | -- |
| None | -- | Positive | -- |
| Dietary fiber (psyllium) | -- | Positive | 314 |
| None | 3 weeks | Positive | -- |
| Peppermint oil, STW-5, psyllium, others | -- | Positive | -- |
| None | -- | Mixed | -- |
| Low-FODMAP, probiotics, fiber | -- | Positive | -- |
권장 복용 시간: With meals and a full glass of water (240 mL minimum); space 1-2 hours from medications
Safety & Side Effects
보고된 부작용
- ⚠ Gas and bloating (common initially; start with low dose and titrate up)
- ⚠ Esophageal/bowel obstruction if taken without adequate water (CRITICAL: always take with full glass of water)
- ⚠ Abdominal cramping at high initial doses
- ⚠ May reduce appetite (feeling of fullness)
알려진 상호작용
- ● May reduce absorption of medications if taken simultaneously (space 1-2 hours)
- ● Lithium (reduced absorption)
- ● Carbamazepine (reduced absorption)
- ● Diabetes medications (may enhance blood sugar lowering; monitor glucose)
일일 최대 섭취 허용량: Well-tolerated up to 30 g/day with adequate fluid intake
건강기능식품을 복용하기 전에 반드시 의료 전문가와 상담하십시오.
Frequently Asked Questions
Does 차전자피 help with 과민성 대장 증후군(IBS)?
Based on 8 studies with 900 participants, there is moderate evidence from clinical studies that 차전자피 may support 과민성 대장 증후군(IBS) management. Our evidence grade is B (Good Evidence).
How much 차전자피 should I take for 과민성 대장 증후군(IBS)?
Studies have used various dosages. A commonly studied range is 5-10 g/day (with adequate water). Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of 차전자피?
Reported side effects may include Gas and bloating (common initially; start with low dose and titrate up), Esophageal/bowel obstruction if taken without adequate water (CRITICAL: always take with full glass of water), Abdominal cramping at high initial doses, May reduce appetite (feeling of fullness). Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for 차전자피 and 과민성 대장 증후군(IBS)?
We rate the evidence as Grade B (Good Evidence). This rating is based on 8 peer-reviewed studies with 900 total participants. The overall direction of effect is positive.
Related Evidence
관련 다른 성분: 과민성 대장 증후군(IBS)
차전자피 다른 건강 상태에 대한 근거
References
- [1] Christian von Muhlenbrock et al.. Best Pract Res Clin Gastroenterol. 2025. The role of dietary fiber in the gastrointestinal tract: when, how and why? doi:10.1016/j.bpg.2025.102080 PubMed
- [2] . Med Lett Drugs Ther. 2025. Comparison chart: Some drugs for irritable bowel syndrome with constipation (IBS-C). doi:10.58347/tml.2025.1721e PubMed
- [3] . Med Lett Drugs Ther. 2025. Drugs for irritable bowel syndrome. doi:10.58347/tml.2025.1721a PubMed
- [4] I Hanna-Jairala et al.. Rev Gastroenterol Mex (Engl Ed). 2025. Survey of Latin American gastroenterologists, specialists in disorders of gut-brain interaction, on the diagnosis and treatment of irritable bowel syndrome … doi:10.1016/j.rgmxen.2025.10.001 PubMed
- [5] . Med Lett Drugs Ther. 2025. Comparison chart: Some drugs for irritable bowel syndrome with diarrhea (IBS-D). doi:10.58347/tml.2025.1721f PubMed
- [6] Pankaj Garg et al.. Gastroenterology. 2024. Psyllium Husk Positively Alters Gut Microbiota, Decreases Inflammation, and Has Bowel-Regulatory Action, Paving the Way for Physiologic Management of Irritable … doi:10.1053/j.gastro.2023.11.019 PubMed
- [7] Silvia Salvatore et al.. Nutrients. 2024. Nutraceuticals and Pain Disorders of the Gut-Brain Interaction in Infants and Children: A Narrative Review and Practical Insights. doi:10.3390/nu16030349 PubMed
- [8] Justyna Przybyszewska et al.. Prz Gastroenterol. 2024. The role and therapeutic effectiveness of Plantago ovata seed husk (psyllium husk) in the prevention and non-pharmacological treatment of gastrointestinal … doi:10.5114/pg.2024.139209 PubMed
- [9] Sandra Utz et al.. Z Gastroenterol. 2024. [Phytotherapeutic recommendations in medical guidelines for the treatment of gastroenterological diseases - a systematic review]. doi:10.1055/a-2279-5045 PubMed
- [10] Sik Yu So et al.. Gastroenterology. 2024. Sex-Dependent Efficacy of Dietary Fiber in Pediatric Functional Abdominal Pain. doi:10.1053/j.gastro.2023.12.011 PubMed
- [11] Silvia Salvatore et al.. Nutrients. 2023. Dietary Fibers in Healthy Children and in Pediatric Gastrointestinal Disorders: A Practical Guide. doi:10.3390/nu15092208 PubMed
- [12] Richard Gearry et al.. Am J Gastroenterol. 2023. Consumption of 2 Green Kiwifruits Daily Improves Constipation and Abdominal Comfort-Results of an International Multicenter Randomized Controlled Trial. doi:10.14309/ajg.0000000000002124 PubMed
- [13] Marcelina Radziszewska et al.. Nutrients. 2023. Nutrition, Physical Activity and Supplementation in Irritable Bowel Syndrome. doi:10.3390/nu15163662 PubMed
- [14] Jagadeesh Menon et al.. J Pediatr Gastroenterol Nutr. 2023. Efficacy of Oral Psyllium in Pediatric Irritable Bowel Syndrome: A Double-Blind Randomized Control Trial. doi:10.1097/MPG.0000000000003622 PubMed
- [15] Daniela Pop et al.. Nutrients. 2023. The Use of Fibers, Herbal Medicines and Spices in Children with Irritable Bowel Syndrome: A Narrative Review. doi:10.3390/nu15204351 PubMed
- [16] Miranda A L van Tilburg et al.. J Pediatr Gastroenterol Nutr. 2023. Efficacy of Oral Psyllium in Pediatric Irritable Bowel Syndrome: A Double-Blind Randomized Control Trial. doi:10.1097/MPG.0000000000003814 PubMed
- [17] Blake J Purtle et al.. Ann Intern Med. 2023. In persons with constipation or IBS-C, kiwifruit vs. psyllium increased spontaneous bowel movements. doi:10.7326/J23-0022 PubMed
- [18] David Gunn et al.. Gut. 2022. Psyllium reduces inulin-induced colonic gas production in IBS: MRI and in vitro fermentation studies. doi:10.1136/gutjnl-2021-324784 PubMed
- [19] Andrew Thomas et al.. Am J Lifestyle Med. 2022. Dietary Modification for the Restoration of Gut Microbiome and Management of Symptoms in Irritable Bowel Syndrome. doi:10.1177/15598276211012968 PubMed
- [20] Diego Currò. Expert Rev Gastroenterol Hepatol. 2022. Current evidence on the therapeutic use of fiber in irritable bowel syndrome. doi:10.1080/17474124.2021.1924057 PubMed
- [21] Pankaj Garg. Turk J Gastroenterol. 2021. Inflammation in Irritable Bowel Syndrome (IBS): Role of Psyllium Fiber Supplementation in Decreasing Inflammation and Physiological Management of IBS. doi:10.5152/tjg.2020.20229 PubMed
- [22] Teodora Surdea-Blaga et al.. Curr Opin Gastroenterol. 2021. Dietary interventions and irritable bowel syndrome - what really works? doi:10.1097/MOG.0000000000000706 PubMed
- [23] Christopher J Black et al.. Lancet Gastroenterol Hepatol. 2020. Efficacy of soluble fibre, antispasmodic drugs, and gut-brain neuromodulators in irritable bowel syndrome: a systematic review and network meta-analysis. doi:10.1016/S2468-1253(19)30324-3 PubMed
- [24] . Med Lett Drugs Ther. 2020. Drugs for Irritable Bowel Syndrome. PubMed
- [25] Paul Moayyedi et al.. J Can Assoc Gastroenterol. 2019. Canadian Association of Gastroenterology Clinical Practice Guideline for the Management of Irritable Bowel Syndrome (IBS). doi:10.1093/jcag/gwy071 PubMed
- [26] Liang Dai et al.. World J Clin Cases. 2019. Irritable bowel syndrome and functional constipation management with integrative medicine: A systematic review. doi:10.12998/wjcc.v7.i21.3486 PubMed
- [27] Magdy El-Salhy et al.. Int J Mol Med. 2017. Dietary fiber in irritable bowel syndrome (Review). doi:10.3892/ijmm.2017.3072 PubMed
- [28] Diego Currò et al.. Br J Pharmacol. 2017. Probiotics, fibre and herbal medicinal products for functional and inflammatory bowel disorders. doi:10.1111/bph.13632 PubMed
- [29] Robert J Shulman et al.. Clin Gastroenterol Hepatol. 2017. Psyllium Fiber Reduces Abdominal Pain in Children With Irritable Bowel Syndrome in a Randomized, Double-Blind Trial. doi:10.1016/j.cgh.2016.03.045 PubMed
- [30] Emma P Halmos. J Gastroenterol Hepatol. 2017. When the low FODMAP diet does not work. doi:10.1111/jgh.13701 PubMed
- [31] Eirini Dimidi et al.. Curr Opin Clin Nutr Metab Care. 2017. Irritable bowel syndrome and diet: where are we in 2018? doi:10.1097/MCO.0000000000000416 PubMed
- [32] Monica R P Rao et al.. Int J Biol Macromol. 2016. Phosphorylation of psyllium seed polysaccharide and its characterization. doi:10.1016/j.ijbiomac.2015.12.043 PubMed
- [33] Daniël R Hoekman et al.. Clin Gastroenterol Hepatol. 2016. Should We Treat Our Pediatric Irritable Bowel Syndrome Patients With Psyllium? doi:10.1016/j.cgh.2016.06.001 PubMed
- [34] Katy E Trinkley et al.. Digestion. 2014. Medication management of irritable bowel syndrome. doi:10.1159/000362405 PubMed
- [35] Shanti Eswaran et al.. Am J Gastroenterol. 2013. Fiber and functional gastrointestinal disorders. doi:10.1038/ajg.2013.63 PubMed
- [36] K E Trinkley et al.. J Clin Pharm Ther. 2011. Treatment of irritable bowel syndrome. doi:10.1111/j.1365-2710.2010.01177.x PubMed
- [37] E P Halmos et al.. Aliment Pharmacol Ther. 2011. Dried plums, constipation and the irritable bowel syndrome. doi:10.1111/j.1365-2036.2011.04719.x PubMed
- [38] Laura E Chouinard. Can J Diet Pract Res. 2011. The role of psyllium fibre supplementation in treating irritable bowel syndrome. doi:10.3148/72.1.2011.48 PubMed
- [39] Eduard Cabré. Curr Opin Clin Nutr Metab Care. 2010. Irritable bowel syndrome: can nutrient manipulation help? doi:10.1097/MCO.0b013e32833b6471 PubMed
- [40] C J Bijkerk et al.. BMJ. 2009. Soluble or insoluble fibre in irritable bowel syndrome in primary care? Randomised placebo controlled trial. doi:10.1136/bmj.b3154 PubMed
- [41] Marie Pirotta. Aust Fam Physician. 2009. Irritable bowel syndrome - The role of complementary medicines in treatment. PubMed
- [42] . Prescrire Int. 2009. Irritable bowel syndrome: a mild disorder; purely symptomatic treatment. PubMed
- [43] Alexander C Ford et al.. BMJ. 2008. Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis. doi:10.1136/bmj.a2313 PubMed
- [44] Baljit Singh. Int J Pharm. 2007. Psyllium as therapeutic and drug delivery agent. doi:10.1016/j.ijpharm.2007.01.028 PubMed
- [45] Reyhaneh Vejdani et al.. Dig Dis Sci. 2006. The efficacy of an herbal medicine, Carmint, on the relief of abdominal pain and bloating in patients with irritable bowel … doi:10.1007/s10620-006-9079-3 PubMed
- [46] Howard Y Chang et al.. Curr Treat Options Gastroenterol. 2006. Current gut-directed therapies for irritable bowel syndrome. doi:10.1007/s11938-006-0013-8 PubMed
- [47] C J Bijkerk et al.. Aliment Pharmacol Ther. 2004. Systematic review: the role of different types of fibre in the treatment of irritable bowel syndrome. doi:10.1111/j.0269-2813.2004.01862.x PubMed
- [48] A Prior et al.. Gut. 1987. Double blind study of ispaghula in irritable bowel syndrome. doi:10.1136/gut.28.11.1510 PubMed
- [49] A Prior et al.. Biomed Pharmacother. 1986. Management of irritable bowel syndrome. PubMed
- [50] G F Longstreth et al.. Ann Intern Med. 1981. Psyllium therapy in the irritable bowel syndrome. A double-blind trial. doi:10.7326/0003-4819-95-1-53 PubMed
- [51] D S Greenbaum et al.. Ann Intern Med. 1981. Psyllium and the irritable bowel syndrome. doi:10.7326/0003-4819-95-5-660_1 PubMed
- [52] A P KLOTZ. JAMA. 1964. IRRITABLE COLON. PubMed
FDA 면책 조항: 이 내용은 미국 식품의약국(FDA)의 평가를 받지 않았습니다. 이 웹사이트의 제품 및 정보는 질병의 진단, 치료, 완치 또는 예방을 목적으로 하지 않습니다. 제시된 근거 등급은 발표된 동료 심사 연구에 대한 우리의 분석에 기반하며, 의학적 조언을 구성하지 않습니다. 건강기능식품 복용을 시작하기 전에 반드시 의료 전문가와 상담하십시오.